Multiple treatment transitions in patients with NMOSD are associated with increased neurological harm, including increased relapse risk and disease progression.
For patients with radiologically isolated syndrome (RIS) predictive of multiple sclerosis (MS), teriflunomide reduced the risk of a demyelinating event over a 2-year period in a phase 3 trial.
2021 MS Innovation Challenge Finalists Announced
Bristol Myers Squibb and Lyfebulb announce 10 finalists chosen for the Lyfebulb-Bristol Myers Squibb “Addressing Unmet Needs in MS: An Innovation Challenge.”
During March 10-11, the following finalists will compete virtually for a grant of $25,000 to further develop their ideas and concepts that will address the unmet needs of people who are experiencing multiple sclerosis (MS). This award will also assist in raising an overall awareness about this chronic disease.
Angie Conley, Founder and CEO of Abilitech Medical
Jason DaSilva, Founder and President of AXS Lab
Luanne Dibernardo, Founder and CEO of Oro Sports
Peter Grande, Co-Founder of MUVE